183 related articles for article (PubMed ID: 35292180)
1. Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues.
Moukarzel LA; Ferrando L; Dopeso H; Stylianou A; Basili T; Pareja F; Da Cruz Paula A; Zoppoli G; Abu-Rustum NR; Reis-Filho JS; Long Roche K; Tew WP; Chi DS; Sonoda Y; Zamarin D; Aghajanian C; O'Cearbhaill RE; Zivanovic O; Weigelt B
Gynecol Oncol; 2022 May; 165(2):239-247. PubMed ID: 35292180
[TBL] [Abstract][Full Text] [Related]
2. Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermia.
Pelz JO; Vetterlein M; Grimmig T; Kerscher AG; Moll E; Lazariotou M; Matthes N; Faber M; Germer CT; Waaga-Gasser AM; Gasser M
Ann Surg Oncol; 2013 Apr; 20(4):1105-13. PubMed ID: 23456378
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of intraperitoneal bevacizumab combined with hyperthermic intraperitoneal chemotherapy in the treatment of patients with ovarian cancer and peritoneal effusion and the effect on serum lncRNA H19 and VEGF levels.
Zhang M; Bao Y; Zhang H; Li D; Mei X; Cheng X
J Obstet Gynaecol; 2023 Dec; 43(1):2204940. PubMed ID: 37186893
[TBL] [Abstract][Full Text] [Related]
4. Combined Interval Cytoreductive Surgery and Carboplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Advanced Primary High-Grade Serous Ovarian Cancer.
Brault C; Brind'Amour A; de Guerke L; Auclair MH; Sideris L; Dubé P; Soucisse M; Tremblay JF; Bernard L; Piedimonte S; Fortin S
Curr Oncol; 2023 Dec; 30(12):10272-10282. PubMed ID: 38132382
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Gelissen JH; Adjei NN; McNamara B; Mutlu L; Harold JA; Clark M; Altwerger G; Dottino PR; Huang GS; Santin AD; Azodi M; Ratner E; Schwartz PE; Andikyan V
Ann Surg Oncol; 2023 Sep; 30(9):5597-5609. PubMed ID: 37358686
[TBL] [Abstract][Full Text] [Related]
6. Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
Zivanovic O; Chi DS; Zhou Q; Iasonos A; Konner JA; Makker V; Grisham RN; Brown AK; Nerenstone S; Diaz JP; Schroeder ED; Langstraat CL; Paroder V; Lakhman Y; Soldan K; Su K; Gardner GJ; Andikyan V; Guo J; Jewell EL; Long Roche K; Troso-Sandoval T; Lichtman SM; Moukarzel LA; Dessources K; Abu-Rustum NR; Aghajanian C; Tew WP; Beumer J; Sonoda Y; O'Cearbhaill RE
J Clin Oncol; 2021 Aug; 39(23):2594-2604. PubMed ID: 34019431
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer.
Dellinger TH; Han ES; Raoof M; Lee B; Wu X; Cho H; He TF; Lee P; Razavi M; Liang WS; Schmolze D; Priceman SJ; Lee S; Lin WC; Lin JF; Kebria M; Hakim A; Ruel N; Stewart DB; Wang EW; Paz BI; Wakabayashi MT; Cristea MC; Rodriguez-Rodriguez L
JCO Precis Oncol; 2022 Mar; 6():e2100239. PubMed ID: 35357903
[TBL] [Abstract][Full Text] [Related]
8. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from ovarian carcinosarcoma.
Lopez-Ramirez F; Sardi A; Studeman K; King MC; Falla-Zuniga LF; Nikiforchin A; Baron E; Nieroda C; Gushchin V; Diaz-Montes T
Eur J Surg Oncol; 2023 Aug; 49(8):1495-1503. PubMed ID: 37068984
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis.
Xia Y; Wang H; Zhang J; Wang Y
Int J Hyperthermia; 2023; 40(1):2165729. PubMed ID: 36775583
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
van Driel WJ; Koole SN; Sikorska K; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AGJ; Verwaal VJ; Kieffer JM; Van de Vijver KK; van Tinteren H; Aaronson NK; Sonke GS
N Engl J Med; 2018 Jan; 378(3):230-240. PubMed ID: 29342393
[TBL] [Abstract][Full Text] [Related]
11. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.
Lim PQ; Han IH; Seow KM; Chen KH
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077477
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for hyperthermic intraperitoneal chemotherapy in ovarian cancer?
Praiss AM; Moukarzel LA; Zivanovic O
Curr Opin Obstet Gynecol; 2023 Feb; 35(1):21-26. PubMed ID: 36595646
[TBL] [Abstract][Full Text] [Related]
13. Ten-year treatment outcomes of consolidation hyperthermic intraperitoneal chemotherapy for ovarian cancer (HIPEC-KOV-03R).
Yoo JG; Kim JH; Park EY; Kim I; Lim MC; Lee SJ
J Gynecol Oncol; 2023 Nov; 34(6):e72. PubMed ID: 37417300
[TBL] [Abstract][Full Text] [Related]
14. HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients.
Menzies AV; Usher EC; Hsu FC; Levine EA; Lentz SS; Kelly MG
Gynecol Oncol; 2022 Nov; 167(2):234-238. PubMed ID: 36085091
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal Fluid Analysis of Advanced Ovarian Cancers after Hyperthermic Intraperitoneal Chemotherapy.
Chen WC; Chang TC; Chou HH; Cheng MH; Hong JJ; Hsieh YS; Cheng CM
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298699
[TBL] [Abstract][Full Text] [Related]
16. Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
Mikkelsen MS; Christiansen T; Petersen LK; Blaakaer J; Iversen LH
J Surg Oncol; 2019 Sep; 120(3):550-557. PubMed ID: 31267569
[TBL] [Abstract][Full Text] [Related]
17. Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90.
Zunino B; Rubio-Patiño C; Villa E; Meynet O; Proics E; Cornille A; Pommier S; Mondragón L; Chiche J; Bereder JM; Carles M; Ricci JE
Oncogene; 2016 Jan; 35(2):261-8. PubMed ID: 25867070
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.
Aronson SL; Lopez-Yurda M; Koole SN; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van Gent MDJM; Arts HJG; van Ham MAPC; van Dam PA; Vuylsteke P; Aalbers AGJ; Verwaal VJ; Van de Vijver KK; Aaronson NK; Sonke GS; van Driel WJ
Lancet Oncol; 2023 Oct; 24(10):1109-1118. PubMed ID: 37708912
[TBL] [Abstract][Full Text] [Related]
19. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
[No Abstract] [Full Text] [Related]
[Next] [New Search]
